Clinical Trial Update: Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial) [Phase 1, Phase 2]

View source ↗

Summary

Aacygene therapy trial (AAV) for CNGB3-related achromatopsia is ongoing in Phase 1/2 to assess safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achromatopsia

Drugs mentioned

• AAV gene therapy for CNGB3 achromatopsia

Snippet

Sponsor: Beacon Therapeutics | Conditions: Achromatopsia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING